The CTSA at the University of Texas Medical Branch (UTMB) is located within the Institute for Translational Science (ITS), one of three free-standing UTMB institutes, established in 2007. In its role as the home for clinical and translational research, the ITS provides primary tenure-earning faculty appointments to 7 early- career translational scientists. Over the past 5 years, we have transformed UTMB's research culture, growing from an institution that solely valued individual laboratory-oriented research to one that embraces multidisciplinary translational team (MTT) approaches to addressing significant health problems. We have developed novel educational curricula, significant clinical research programs in special populations with multi- site clinical trials (CTs), and provided leadership in the Texas Regional CTSA consortium (TRCC) and nationally. The mission of the UTMB CTSA hub is to support the health goals of the nation by generating, testing and disseminating integrative team science, education and best practices through stakeholder involvement at all stages. Managed by a continuous improvement model using an Innovation Scorecard, the UTMB CTSA will address four specific aims, to: 1) Train a diverse workforce in the authentic skills needed to advance all phases of translational research. We have used the team environment as an educational framework to support the training of diverse learning communities. Our innovation, entrepreneurship, and team leadership curricula will be used to instill focused, career stage-appropriate competencies in our trainees. We have led in sharing and disseminating innovative educational content in entrepreneurship and team science throughout the consortium. 2). Engage stakeholders across all phases of translational research and CTs. We will extend our substantial bidirectional interactions with stakeholders from the community, patient advocacy groups, healthcare providers and our Health System to assess health needs, set CTSA priorities and disseminate competencies. 3). Integrate quality systems through all types of translational research, including CTs in special populations. We have provided leadership to a university-wide plan for sustainable support for high-quality CTs through the Office of Clinical Research, supported by an experienced director, an interoperable Clinical Trial Management System and staff to provide streamlined support for all phases of CT start-up, quality assurance monitoring, study management and GCP training. 4). Advance the conduct of translational research through MTT-based innovation. The UTMB CTSA hub is unique in the national consortium in its systematic application of a hybrid industry-academic MTT model, and have developed an evidence base on the formation, evaluation, impact and trajectories of successful MTTs. We will stimulate MTT innovation by promoting team development, leadership development by a unique Leadership Development Academy, and advancement of therapeutics and devices into Phase I/II CTs in our ?Innovations in Molecular Therapeutics and Devices? Optional Module.

Public Health Relevance

The UTMB CTSA hub will support bidirectional translational research, moving discoveries from the bench to the bedside, by training a capable workforce using our unique multidisciplinary translational teams and innovative educational programs that build real-world skills. Our hub will serve to foster high-quality clinical research, develop best practices in team-based translations, participate in inter-institutional data-sharing, and function as an efficient site for multi-site clinical trials in understudied populations. In this manner, the UTMB CTSA hub will be an important contributor to achieving the goals of the national consortium.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR001439-04
Application #
9479715
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Wilde, David B
Project Start
2015-08-18
Project End
2020-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas Med Br Galveston
Department
Surgery
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Vincent, Kathleen Listiak; Moss, John A; Marzinke, Mark A et al. (2018) Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. PLoS One 13:e0201952
Ochoa, Lorenzo F; Kholodnykh, Alexander; Villarreal, Paula et al. (2018) Imaging of Murine Whole Lung Fibrosis by Large Scale 3D Microscopy aided by Tissue Optical Clearing. Sci Rep 8:13348
Rontoyanni, Victoria G; Malagaris, Ioannis; Herndon, David N et al. (2018) Skeletal Muscle Mitochondrial Function is Determined by Burn Severity, Sex, and Sepsis, and is Associated With Glucose Metabolism and Functional Capacity in Burned Children. Shock 50:141-148
Soto-Acosta, Ruben; Xie, Xuping; Shan, Chao et al. (2018) Fragile X mental retardation protein is a Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA. Elife 7:
Cambiaso-Daniel, Janos; Rontoyanni, Victoria G; Foncerrada, Guillermo et al. (2018) Correlation between invasive and noninvasive blood pressure measurements in severely burned children. Burns 44:1787-1791
Rossi, Shannan L; Ebel, Gregory D; Shan, Chao et al. (2018) Did Zika Virus Mutate to Cause Severe Outbreaks? Trends Microbiol 26:877-885
Liu, Zhiqing; Tian, Bing; Chen, Haiying et al. (2018) Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem 151:450-461
Langsjoen, Rose M; Haller, Sherry L; Roy, Chad J et al. (2018) Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models. MBio 9:
Capek, Karel D; Sousse, Linda E; Hundeshagen, Gabriel et al. (2018) Contemporary Burn Survival. J Am Coll Surg 226:453-463
Raji, Mukaila A; Kuo, Yong-Fang; Adhikari, Deepak et al. (2018) Decline in opioid prescribing after federal rescheduling of hydrocodone products. Pharmacoepidemiol Drug Saf 27:513-519

Showing the most recent 10 out of 173 publications